BioSymetrics

Throwback time! 🎃 Here’s a blast from the past from our Halloween costume party a couple of years ago, where creativity, costumes, and laughs took centre stage! Wishing you all a frightfully fun Halloween from our team to yours! 👻 #Halloween #TeamFun #Throwback

Next up in our Pheno-Type highlight series is Michele Arena, PMP, Director of Project Management. In this feature, she talks about her transition from clinical practice to project management, ultimately landing at BioSymetrics. Click through to read more! https://lnkd.in/gPMtWGy5 #ai #drugdiscovery

A joy of being based in Canada and the United States is that we get to celebrate two Thanksgivings. (Whether this translates to twice the turkey is anyone’s guess!) Happy Thanksgiving Day to our Canadian team members! #ThanksgivingDay

Our next entry in our Pheno-Type series, highlighting our team members, features Kevin Ha, Head of Data Science, Genomics. In this feature, he talks about his journey from bioinformatics to BioSymetrics. Click through to read more! https://lnkd.in/eHSR-zik #ai #drugdiscovery

We are excited to announce our strategic partnership with Moleculera Biosciences to combine our AI-driven Elion platform with Moleculera’s expansive biorepository and bioinformatics dataset. Together, we aim to develop advanced predictive treatment algorithms that can revolutionize how clinicians identify and treat immune-mediated neurologic and psychiatric disorders – eliminating trial and error and improving patient outcomes. Read our press release here: https://lnkd.in/gRyat5Xf #AI #Bioinformatics #Neurology #PrecisionMedicine

We are resuming our Pheno-Type series! Victoria Catterson, Vice President of Data Science Research, features in our first team member highlight of this series. In this feature, she talks about her leap from diagnostics in power equipment to BioSymetrics. Click through to read more! https://lnkd.in/dAuQPyk4 #ai #drugdiscovery

We collaborated with a group from Parent Project Muscular Dystrophy, from Leiden University Medical Center and University of Florida, to identify biomarkers of disease progression in Duchenne muscular dystrophy (#DMD). A preprint of our work is now available on medRxiv. Special thanks to Shahrzad Hosseini and Simon Eng for leading this work for BioSymetrics! See the preprint here: https://lnkd.in/d7jhJRWn

Join us as we celebrate the 5th anniversary of BioSymetrics' Canadian subsidiary this week! We started our Canadian operations in 2019 from a little office space in Toronto. Since then our Canadian team has expanded beyond Toronto, to Charlottetown on the east coast and Vancouver on the west coast! Our Canadian Machine Learning team has been at the forefront of various BioSymetrics technologies, including our proprietary Phenograph, Computer Vision, and MOA Miner platforms. Special thanks to Gabriel Musso, Victoria Catterson , and Kevin Ha for co-founding our Canadian team and paving the way for our future success!

At BioSymetrics, we have a team with diverse backgrounds and skillsets, based in various locations throughout North America. Over the coming months, we will highlight our team members and celebrate their journeys to their current roles at BioSymetrics through our Pheno-Type series. Follow us and stay tuned! #Biotech #AIDrugDiscovery #MachineLearning

We are delighted to kick off an exciting new collaboration with Christine Bear, PhD from Molecular Medicine at The Hospital for Sick Children (SickKids), to unlock targeted therapies for people with Cystic Fibrosis (CF). The recent breakthrough drug Trikafta™ has been transformative for patients with the F508del mutation on the CFTR gene: the most common cause of CF. But there are over 400 disease-causing gene variants of the CFTR gene, and not all patients with the F508del mutation respond to Trikafta™. Similarly, the SickKids CF Centre found that tissue samples carrying CF-causing mutations show considerable variability in Trikafta™ response size in the lab. This collaboration will use machine learning to sift through phenotypic and genetic data for responders and non-responders, to help identify those people who are most likely to benefit from Trikafta™ and emerging therapies. “The results of this project could be so impactful to the lives of those living with Cystic Fibrosis. I’m gratified to be involved in this important work.” —Victoria Catterson, VP of Data Science Research at BioSymetrics #CysticFibrosis #MachineLearning